{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T19:27:26Z","timestamp":1780082846990,"version":"3.54.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100014717","name":"National Outstanding Youth Science Fund Project of National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81971716"],"award-info":[{"award-number":["81971716"]}],"id":[{"id":"10.13039\/100014717","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>I-125 seeds brachytherapy (ISB) has been used to improve the clinical effectiveness of transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). We aim to appraise the safety and clinical efficacy of combined ISB and TACE for the treatment of subcapsular HCC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>A retrospective investigative study extending from January 2017 to December 2020, involved individuals suffering from subcapsular HCC, who were subjected to TACE treatment with or without ISB in our center. The clinical effectiveness was compared between 2 groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Sixty-four patients, in total, with subcapsular HCC had to undergo TACE with (n\u2009=\u200932) or without (n\u2009=\u200932) ISB in our center. After CT-guided ISB, only 2 (6.3%) patients experienced a self-limited pneumothorax. Combined treatment resulted in a significantly higher complete response (56.3% vs. 18.8%,<jats:italic>P<\/jats:italic>\u2009=\u20090.002) and total response (90.7% vs. 59.4%,<jats:italic>P<\/jats:italic>\u2009=\u20090.004) rates than that of TACE alone. In comparison to the TACE alone group, the median progression-free survival was substantially longer in the combined treatment group (11\u00a0months vs. 5\u00a0months,<jats:italic>P<\/jats:italic>\u2009=\u20090.016). Further, 15 and 28 patients in combined and TACE alone groups respectively died within the follow-up. The median OS was comparable between combined and TACE alone groups (22\u00a0months vs. 18\u00a0months,<jats:italic>P<\/jats:italic>\u2009=\u20090.529).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Combined TACE and ISB therapy is a safe treatment method for individuals suffering from subcapsular HCC. When compared, combined treatment had significantly enhanced clinical efficacy as a subcapsular HCC therapy, in comparison to TACE alone.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12876-022-02356-0","type":"journal-article","created":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T05:02:39Z","timestamp":1654059759000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["I-125 seeds brachytherapy with transcatheter arterial chemoembolization for subcapsular hepatocellular carcinoma"],"prefix":"10.1186","volume":"22","author":[{"given":"Fu-Lei","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-Zhong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-Fan","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-He","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,1]]},"reference":[{"key":"2356_CR1","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1053\/j.semdp.2016.12.011","volume":"34","author":"J Hartke","year":"2017","unstructured":"Hartke J, Johnson M, Ghabril M. The diagnosis and treatment of hepatocellular carcinoma. Semin Diagn Pathol. 2017;34:153\u20139.","journal-title":"Semin Diagn Pathol"},{"key":"2356_CR2","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1067\/j.cpradiol.2015.04.004","volume":"44","author":"T Clark","year":"2015","unstructured":"Clark T, Maximin S, Meier J, et al. Hepatocellular carcinoma: review of epidemiology, screening, imaging diagnosis, response assessment, and treatment. Curr Probl Diagn Radiol. 2015;44:479\u201386.","journal-title":"Curr Probl Diagn Radiol"},{"key":"2356_CR3","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1055\/s-2007-1007122","volume":"19","author":"JM Llovet","year":"1999","unstructured":"Llovet JM, Br\u00fa C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329\u201338.","journal-title":"Semin Liver Dis"},{"key":"2356_CR4","first-page":"952","volume":"25","author":"H Zhang","year":"2020","unstructured":"Zhang H, Yang A, Zhang J. Efficacy of transcatheter arterial chemoembolization combined with 125I seed implantation and three-dimensional conformal radiotherapy in advanced primary hepatocellular carcinoma. J BUON. 2020;25:952\u20138.","journal-title":"J BUON"},{"key":"2356_CR5","first-page":"1208","volume":"42","author":"J Bruix","year":"2005","unstructured":"Bruix J, Sherman M. Practice guidelines committee, american association for the study of liver diseases. Manag Hepatocell Carcinoma Hepatol. 2005;42:1208\u201336.","journal-title":"Manag Hepatocell Carcinoma Hepatol"},{"key":"2356_CR6","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1186\/s12885-017-3545-5","volume":"17","author":"FX Wu","year":"2017","unstructured":"Wu FX, Chen J, Bai T, et al. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B\/C hepatocellular carcinoma. BMC Cancer. 2017;17:645.","journal-title":"BMC Cancer"},{"key":"2356_CR7","doi-asserted-by":"publisher","first-page":"5752","DOI":"10.1007\/s00330-019-06157-0","volume":"29","author":"Z Yang","year":"2019","unstructured":"Yang Z, Zou R, Zheng Y, et al. Lipiodol deposition in portal vein tumour thrombus predicts treatment outcome in HCC patients after transarterial chemoembolisation. Eur Radiol. 2019;29:5752\u201362.","journal-title":"Eur Radiol"},{"key":"2356_CR8","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1016\/j.ijrobp.2011.03.019","volume":"82","author":"SM Yoon","year":"2012","unstructured":"Yoon SM, Lim YS, Won HJ, et al. Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes. Int J Radiat Oncol Biol Phys. 2012;82:2004\u201311.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2356_CR9","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1007\/s12032-011-0145-0","volume":"29","author":"ZJ Niu","year":"2012","unstructured":"Niu ZJ, Ma YL, Kang P, et al. Transarterial chemoembolization compared with conservative treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus: using a new classification. Med Oncol. 2012;29:2992\u20137.","journal-title":"Med Oncol"},{"key":"2356_CR10","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/j.ejso.2019.03.042","volume":"45","author":"X Xiang","year":"2019","unstructured":"Xiang X, Lau WY, Wu ZY, et al. Transarterial chemoembolization versus best supportive care for patients with hepatocellular carcinoma with portal vein tumor thrombus: a multicenter study. Eur J Surg Oncol. 2019;45:1460\u20137.","journal-title":"Eur J Surg Oncol"},{"key":"2356_CR11","doi-asserted-by":"publisher","first-page":"4756147","DOI":"10.1155\/2018\/4756147","volume":"2018","author":"S Shiina","year":"2018","unstructured":"Shiina S, Sato K, Tateishi R, et al. Percutaneous ablation for hepatocellular carcinoma: comparison of various ablation techniques and surgery. Can J Gastroenterol Hepatol. 2018;2018:4756147.","journal-title":"Can J Gastroenterol Hepatol"},{"key":"2356_CR12","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1007\/s00330-019-06497-x","volume":"30","author":"A Worakitsitisatorn","year":"2020","unstructured":"Worakitsitisatorn A, Lu DS, Lee MW, et al. Percutaneous thermal ablation of subcapsular hepatocellular carcinomas: influence of tumor-surface contact and protrusion on therapeutic efficacy and safety. Eur Radiol. 2020;30:1813\u201321.","journal-title":"Eur Radiol"},{"key":"2356_CR13","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.brachy.2018.12.008","volume":"18","author":"J Li","year":"2019","unstructured":"Li J, Zhang L, Xie Q, et al. 125I seeds implantation for treating residual hepatocellular carcinoma located beneath the diaphragm after transcatheter arterial chemoembolization. Brachytherapy. 2019;18:420\u20135.","journal-title":"Brachytherapy"},{"key":"2356_CR14","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/hep.24199","volume":"53","author":"J Bruix","year":"2011","unstructured":"Bruix J, Sherman M. American association for the study of liver diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020\u20132.","journal-title":"Hepatology"},{"key":"2356_CR15","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52\u201360.","journal-title":"Semin Liver Dis"},{"key":"2356_CR16","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.4103\/jcrt.JCRT_1587_20","volume":"16","author":"Y Li","year":"2020","unstructured":"Li Y, Li H, Hu H, et al. Efficacy and safety of transcatheter arterial chemoembolization combined with either 125I seed implantation or apatinib in hepatocellular carcinoma with portal vein tumor thrombosis: A retrospective comparative study. J Cancer Res Ther. 2020;16:1691\u20137.","journal-title":"J Cancer Res Ther"},{"key":"2356_CR17","first-page":"1187","volume":"31","author":"H Kaba","year":"2004","unstructured":"Kaba H, Fukuda H, Yamamoto S, et al. Reliability at the national cancer institute-common toxicity criteria version 2.0. Gan To Kagaku Ryoho. 2004;31:1187\u201392.","journal-title":"Gan To Kagaku Ryoho"},{"key":"2356_CR18","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ejrad.2017.04.002","volume":"91","author":"F Liu","year":"2017","unstructured":"Liu F, Yu X, Cheng Z, et al. Comparison of ultrasonography-guided percutaneous microwave ablation for subcapsular and nonsubcapsular hepatocellular carcinoma. Eur J Radiol. 2017;91:93\u20138.","journal-title":"Eur J Radiol"},{"key":"2356_CR19","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1007\/s00261-020-02830-x","volume":"46","author":"C Liu","year":"2021","unstructured":"Liu C, He J, Li T, et al. Evaluation of the efficacy and postoperative outcomes of hydrodissection-assisted microwave ablation for subcapsular hepatocellular carcinoma and colorectal liver metastases. Abdom Radiol (NY). 2021;46:2161\u201372.","journal-title":"Abdom Radiol (NY)"},{"key":"2356_CR20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.5152\/dir.2019.18543","volume":"26","author":"F Wang","year":"2020","unstructured":"Wang F, Ma J, Wu L, et al. Percutaneous cryoablation of subcapsular hepatocellular carcinoma: a retrospective study of 57 cases. Diagn Interv Radiol. 2020;26:34\u20139.","journal-title":"Diagn Interv Radiol"},{"key":"2356_CR21","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s00595-017-1607-6","volume":"48","author":"K Araki","year":"2018","unstructured":"Araki K, Kubo N, Watanabe A, et al. Systematic review of the feasibility and future of laparoscopic liver resection for difficult lesions. Surg Today. 2018;48:659\u201366.","journal-title":"Surg Today"},{"key":"2356_CR22","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.dld.2016.06.007","volume":"48","author":"M Li","year":"2016","unstructured":"Li M, He J, Pan M, et al. Iodine-125 implantation plus transarterial chemoembolization for the treatment of hepatocellular carcinoma of 3\u20135cm: A propensity score matching study. Dig Liver Dis. 2016;48:1082\u20137.","journal-title":"Dig Liver Dis"},{"key":"2356_CR23","doi-asserted-by":"publisher","first-page":"242","DOI":"10.3904\/kjim.2015.112","volume":"31","author":"MJ Song","year":"2016","unstructured":"Song MJ, Bae SH, Lee JS, et al. Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma. Korean J Intern Med. 2016;31:242\u201352.","journal-title":"Korean J Intern Med"},{"key":"2356_CR24","first-page":"1414","volume":"24","author":"Y Zeng","year":"2019","unstructured":"Zeng Y, Mao Y, Shi Z, et al. Observation of therapeutic effect of 125I seed implantation combined with chemotherapy and antiviral therapy on HBV-related liver cancer. J BUON. 2019;24:1414\u20139.","journal-title":"J BUON"},{"key":"2356_CR25","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1053\/jhep.2003.50047","volume":"37","author":"JM Llovet","year":"2003","unstructured":"Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology. 2003;37:429\u201342.","journal-title":"Hepatology"},{"key":"2356_CR26","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3348\/kjr.2018.19.2.237","volume":"19","author":"L Zheng","year":"2018","unstructured":"Zheng L, Li HL, Guo CY, et al. Comparison of the efficacy and prognostic factors of transarterial chemoembolization plus microwave ablation versus transarterial chemoembolization alone in patients with a large solitary or multinodular hepatocellular carcinomas. Korean J Radiol. 2018;19:237\u201346.","journal-title":"Korean J Radiol"},{"key":"2356_CR27","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1007\/s00270-020-02569-4","volume":"43","author":"I Bargellini","year":"2020","unstructured":"Bargellini I, Mosconi C, Pizzi G, et al. Yttrium-90 radioembolization in unresectable intrahepatic cholangiocarcinoma: results of a multicenter retrospective study. Cardiovasc Intervent Radiol. 2020;43:1305\u201314.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"2356_CR28","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3390\/jcm8010055","volume":"8","author":"A Saini","year":"2019","unstructured":"Saini A, Wallace A, Alzubaidi S, et al. History and evolution of yttrium-90 radioembolization for hepatocellular carcinoma. J Clin Med. 2019;8:55.","journal-title":"J Clin Med"},{"key":"2356_CR29","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1007\/s00270-021-02800-w","volume":"44","author":"C Mosconi","year":"2021","unstructured":"Mosconi C, Solaini L, Vara G, et al. Transarterial chemoembolization and radioembolization for unresectable intrahepatic cholangiocarcinoma-a systemic review and meta-analysis. Cardiovasc Intervent Radiol. 2021;44:728\u201338.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"2356_CR30","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1053\/j.gastro.2016.08.029","volume":"151","author":"R Salem","year":"2016","unstructured":"Salem R, Gordon AC, Mouli S, et al. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2016;151:1155-1163.e2.","journal-title":"Gastroenterology"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-022-02356-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-022-02356-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-022-02356-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T13:46:48Z","timestamp":1700660808000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-022-02356-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2356"],"URL":"https:\/\/doi.org\/10.1186\/s12876-022-02356-0","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,1]]},"assertion":[{"value":"22 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This single-center study was approved by Ethics Committee of Affiliated Jiangyin Hospital, Medical College of Southeast University. Written informed consent was waived due to the retrospective nature. All methods were carried out in accordance with Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The relevant patients provided informed consent for publication of the images in Fig.\u00a0.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"273"}}